These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prospective intraindividual comparison of 18F-PSMA-7Q and 18F-DCFPyL PET/CT in patients with newly diagnosed prostate cancer.
    Author: Liu Y, Zhang X, Liu J, Zhang J, Xu B.
    Journal: Nucl Med Commun; 2022 Jun 01; 43(6):725-730. PubMed ID: 35560134.
    Abstract:
    OBJECTIVE: Fluorine 18 (18F)-2-(3-{1-Carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (DCFPyL) is an early 18F-labeled prostate-specific membrane antigen (PSMA) targeted PET tracer that has shown promise in the diagnostic workup of prostate cancer and was recently approved by the US Food and Drug Administration. 18F-PSMA-7Q is a novel 18F-labeled PSMA-ligand PET tracer designed and synthesized by our team. This study compared the tracer-specific positron emission tomography/computed tomography (PET/CT) characteristics of 18F-PSMA-7Q with those of 18F-DCFPyL in patients with newly diagnosed prostate cancer. METHODS: Ten patients received similar doses of 18F-DCFPyL and 18F-PSMA-7Q 48 h apart and were imaged 1 h after injection on the same PET/CT scanner. Normal-organ biodistribution and tumor uptake were quantified using maximum and mean standardized uptake values (SUVmax and SUVmean), and all lesions were assigned a molecular imaging PSMA (miPSMA) score based on Prostate Cancer Molecular Imaging Standardized Evaluation criteria. RESULTS: Seventeen lesions were detected in the 10 patients by both 18F-DCFPyL and 18F-PSMA-7Q. No statistically significant difference was observed when comparing the SUVmax and SUVmean of 18F-DCFPyL and 18F-PSMA-7Q in the lesions and parotid gland. The κ value for the miPSMA scores of the lesions between the two tracers was 0.907, indicating excellent agreement. CONCLUSION: 18F-PSMA-7Q can be used in clinical research as reliably as 18F-DCFPyL. The limited urinary excretion of 18F-PSMA-7Q may represent a potential advantage over 18F-DCFPyL for detection of lesions in the pelvis, which need to be verified by further studies.
    [Abstract] [Full Text] [Related] [New Search]